Quentin de Berny

Quentin de Berny

Auto-generated profile, based on publicly available information

Quentin de Berny

Department of Nephrology Dialysis Transplantation, Amiens University Hospital, Amiens, France

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
VJValentine Jacob
Valentine Jacob
QBQuentin de Berny
Quentin de Berny
FBFrançois Brazier
François Brazier
CPClaire Presne
Claire Presne
JLJulien LION
Julien LION
NGNicolas Guillaume
Nicolas Guillaume
Extracellular vesicles (EVs) have a key role in intercellular communication. We hypothesized that EVs are biomarkers of nephropathy or kidney allograft rejection. We screened patients with chronic kidney disease (CKD) and kidney transplant (KT) recipients. We measured the urine and plasma levels of total EVs overall and EV subpopulations (positive for podocalyxin, aquaporin-1, CD133, CD144, CD19, CD3, CD16, CD56, or CD41). We included 92 patients with CKD, 70 KT recipients, and 33 healthy volunteers. In CKD, the total urine EV concentration was correlated positively with the estimated glomerular filtration rate (eGFR), but none of the subpopulations was identified as a potential biomarker of nephropathy. Among the KT recipients, 30 had good allograft function and 40 had allograft disease (13 with antibody-mediated rejections (ABMR), 12 with T-cell-mediated rejection (TCMR), and 15 with allograft dysfunction). Patients with ABMR had low plasma levels of EVs derived from B-cells, T-cells, and endothelium (p = 0.003, 0.009, and 0.005, respectively). Patients with TCMR had a low urine level of EVs derived from endothelium (p = 0.05). EVs derived from B-cells, T-cells, and endothelium might be biomarkers of kidney allograft rejection. However, we did not identify biomarkers of nephropathy in CKD.

29 April 2024 in Clinical Kidney Journal
Verified
Journal Article
Open access
PDF file
QBQuentin de Berny
Quentin de Berny
MDMomar Diouf
Momar Diouf
RMRafik Mesbah
Rafik Mesbah
TQThomas Quemeneur
Thomas Quemeneur
CLCéline Lebas
Céline Lebas
DTDimitri Titeca-Beauport
Dimitri Titeca-Beauport
The anti-neutrophil cytoplasmic antibody (ANCA) renal risk score (ARRS) for predicting renal survival in ANCA-associated vasculitis (AAV) had not previously been validated in adults over 65 years of age and presenting impairments associated with an aging kidney, a high cardiovascular comorbidity burden and prevalent microscopic polyangiitis. We retrospectively studied a cohort of 192 patients over 65 years of age [median (interquartile range) age: 73 (68–78) years], including 17.2% with renal-limited vasculitis, 49.5% with microscopic polyangiitis and 33.3% with granulomatosis with polyangiitis, at six centres in northern France. The primary study endpoint was the cumulative incidence of end-stage kidney disease (ESKD, maintenance of dialysis for at least 3 months) at 12 months, with death considered as a competing event. The median serum creatinine concentration at diagnosis was 300 (202–502) µmol/L, and 48 (25.0%) patients required dialysis at presentation. The ARRS was high in 43 (22.4%) patients, medium in 106 (55.2%) and low in 43 (22.4%). The cumulative incidence of ESKD at 12 months was 0% in the low-risk group, 13.0% (interquartile range 7.6–20.0) in the medium-risk group and 44.0% (29.0–58.0) in the high-risk group (P < .001). In the subgroup of 149 patients presenting a medium or high score, the ARRS had a C-index of 0.66 (0.58–0.74) for the prediction of ESKD at 12 months; this rose to 0.86 (0.80–0.90) when dialysis status at diagnosis was included. The ARRS was a poor predictor of kidney survival at 12 months among patients over 65 years of age with renal AAV involvement—especially in the high ARRS group. The addition of dialysis status at diagnosis as an additional clinical parameter might improve the predictive performance of the ARRS. Watch the video abstract of this contribution https://academic.oup.com/ckj/pages/author_videos

4 July 2025 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
QBQuentin de Berny
Quentin de Berny
VSValéry Salle
Valéry Salle
CRCédric Renard
Cédric Renard
PMPhilippe-Edouard Merle
Philippe-Edouard Merle
NGNelly Guilain
Nelly Guilain
OFOphélie Fourdinier
Ophélie Fourdinier
Vacuolar myopathy is a muscle disease characterized by inefficient autophagy and the accumulation of intracytoplasmic degradation products in autophagic vacuoles. Acquired vacuolar myopathy associated with monoclonal gammopathy is a novel clinical entity first described in 2019. The objective of the present article is to describe the first case of an acquired vacuolar myopathy associated with lambda light chain myeloma. A 52-year-old man was admitted to our nephrology department for acute kidney injury and was diagnosed with lambda light chain multiple myeloma. The patient presented with supraventricular arrythmia and developed rapidly progressing muscle weakness of the face and all four limbs, with a myogenic electromyographic pattern. A muscle biopsy highlighted muscle fibre vacuoles and lambda light chain deposits. Cardiac magnetic resonance imaging revealed concentric hypertrophy and subepicardial areas of fibrosis that were suggestive of an infiltrative disease. There were no signs of amyloidosis. Treatment with a combination of bortezomib, lenalidomide and dexamethasone gave a good hematologic response, and the patient recovered near-normal levels of muscle strength in the following six months. The number of episodes of arrythmia decreased. Clinicians should be aware that lambda light chain myeloma may cause lambda light-chain deposits within muscle fibres and vacuolar myopathy. A corticosteroid-sparing strategy for vacuolar myopathy does not appear to be necessary when the course of the myeloma is favourable. Myopathy associated with monoclonal gammopathy is an emerging entity. Given that monoclonal gammopathy is very common in older adults, the appearance of muscle impairments in this context could prompt the physician to consider the initiation of corticosteroids, immunosuppressive agents, or intravenous immunoglobulins. Electromyography and muscle biopsy results can guide the diagnosis.

1 February 2024 in American Journal of Physiology-Renal Physiology
Verified
Journal Article
Open access
QBQuentin de Berny
Quentin de Berny
CSCamille Saint-Jacques
Camille Saint-Jacques
ASAline Santin
Aline Santin
SMSarah Mattioni
Sarah Mattioni
OSOlivier Steichen
Olivier Steichen
JHJean-Philippe HAYMANN
Jean-Philippe HAYMANN
The urine concentration impairment in sickle cell anemia is an osmotic diuresis related to an impaired renal medullary gradient leading to an ADH plateau effect. The fasting plasma ADH was high in the context of a basic state of close-to-maximal urine concentration probably driven by short nephrons maintaining a cortex-outer medullary gradient (about 400 milliosmoles). The patients had a low daily osmoles intake without evidence of thirst dysregulation so no one experienced polyuria.

4 November 2026 in Kidney360
Verified
Journal Article
Open access
GBGérémy Blot
Gérémy Blot
QBQuentin de Berny
Quentin de Berny
LLLoïc Louvet
Loïc Louvet
LVLudivine Vasseur
Ludivine Vasseur
CACarine Avondo
Carine Avondo
LHLucie Hénaut
Lucie Hénaut
Background: Calcific aortic valve disease (CAVD) is prevalent in chronic kidney disease (CKD), yet no pharmacological therapies exist. Preclinical models rarely incorporate CKD–mineral and bone disorder (CKD-MBD) features, limiting translational potential. We aimed to develop a comprehensive preclinical approach to study CKD-associated CAVD, suitable for standardized assessment of therapies on valvular, cardiac, vascular, and skeletal outcomes. Methods: Eight-week-old male Sprague Dawley rats were assigned to a control group (n=17) fed standard chow or an adenine-phosphate group (AP, n=21) fed chow supplemented with 0.3% adenine and 1.15% phosphate. Diets were enriched with 20% lactose and 19% casein to facilitate phosphate absorption and calcium solubility. Cardiac function was evaluated by echocardiography at baseline, week 5, and 9, with concurrent blood sampling. Aortic valve (AV) calcification was assessed by Alizarin Red and Osteosense staining, and aortic calcium quantified using O-Cresolphthalein Complexone. Gene expression in the aorta and left ventricle (LV) was analyzed by RNA-seq at week 9, and bone microarchitecture assessed by micro-CT. Results: AP rats showed progressive increases in serum creatinine, calcium-phosphorus product, and uremic toxins. By week 9, they exhibited significant AV calcification, with reduced valve area and cusp separation. Relative wall thickness and LV histology were preserved, though transcriptomics revealed early priming toward inflammation and fibrosis. AP rats’ aortas showed calcification, osteogenic features and reduced systolic expansion. Bone analysis revealed cortical thinning and increased porosity, while trabecular bone showed reduced trabecular number, increased trabecular spacing, and compensatory thickening. Together with elevated PTH and FGF23 levels, these changes suggest high bone turnover due to secondary hyperparathyroidism and are correlated with the extent of AV calcification. Conclusions: These results underscore the model’s translational relevance, addressing multiple facets of CKD-MBD and supporting its use for preclinical screening of novel therapies targeting CKD-associated cardiovascular calcification.